Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 11/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13631388 | 0.88 | RAB9A (0.51) | TACR3PREPRAB9AMEN1LMNA | |
| SCHEMBL4355252 | 0.85 | TACR3 (0.53) | TACR3SLC2A1ADORA2AADORA1KDM4E | |
| SCHEMBL4367561 | 0.79 | SLC6A9 (0.41) | TACR3SLC2A1PREPFAPADORA2A | |
| SCHEMBL3244195 | 0.78 | SLC6A9 (0.59) | — | |
| SCHEMBL4356702 | 0.77 | TACR3 (0.56) | TACR3SLC2A1ADORA2AADORA1KDM4E | |
| SCHEMBL3237083 | 0.77 | POLB (0.42) | KDM4ELMNA | |
| SCHEMBL3242223 | 0.77 | NPC1 (0.40) | RAB9AKDM4ELMNAKMT2A | |
| SCHEMBL13619226 | 0.76 | TACR3 (0.53) | TACR3SLC2A1ADORA2AADORA1LMNA | |
| SCHEMBL4361695 | 0.76 | TACR3 (0.53) | TACR3SLC2A1ADORA2AADORA1TACR2 | |
| SCHEMBL3245182 | 0.76 | HPGD (0.45) | MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006067430-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286828-A1 | 2-AMINO-1-PHENYLETHYLCARBOXAMIDE DERIVATIVES | PNMT, SLC18A2, COMT | TACR3 2005/4885SLC2A1 1844/4885TRPV4 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.